CPAP ( Continous Positive Airway Pressure) Tedavisinin Oksidatif Stres ve Pro- İnflamatuar Sürece Olan Etkisi

SARI, U Serpil; YILMAZ, Hikmet; ALDEMİR, Eda ÇAKIROĞLU; KORKMAZ, Tuğba KORKMAZ; Dinç Horasan, Gönül; OKTAN, Bilge; KISABAY, Ayşin

CPAP ( Continous Positive Airway Pressure) Tedavisinin Oksidatif Stres ve Pro- İnflamatuar Sürece Olan Etkisi

Ayşin KISABAY, (Celal Bayar Üniversitesi)

U Serpil SARI, (Celal Bayar Üniversitesi)

Eda ÇAKIROĞLU ALDEMİR, (Celal Bayar Üniversitesi)

Bilge OKTAN, (Celal Bayar Üniversitesi)

Tuğba KORKMAZ KORKMAZ, (Celal Bayar Üniversitesi)

Gönül Dinç HORASAN, (Celal Bayar Üniversitesi)

Hikmet YILMAZ (Celal Bayar Üniversitesi)

Journal of Neurological Sciences (Turkish)

1 1

Yıl: 2016 Cilt: 33 Sayı: 2 Sayfa Aralığı: 264 - 277 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

CPAP ( Continous Positive Airway Pressure) Tedavisinin Oksidatif Stres ve Pro- İnflamatuar Sürece Olan Etkisi

Öz:

Giriş: Obstruktif Uyku Apne Sendromu, hipertansiyon, glukoz metabolizmasında bozulma, obesite ve metabolik sendrom, kalp hastalıkları, kan basıncında artma ,kolesterol. trigliserit, homosistein yüksekliği ve koagülasyonda artışa neden olma; aterosklerotik süreçlerin gelişiminde rolü olması nedeniyle bağımsız bir risk faktördür. Total kolesterol ve trigliserit değerlerinin düştüğü, HDL kolesterolunun yükseldiği, sempatik sistem aktivasyonunun, visseral obesitenin, insülin direncinin ve kan basıncının azaldığı, glukoz tolerans testinin düzeldiği görülmüştür. Materyal ve Metod: Özgeçmişinde hiçbir hastalığı olmayan ve yapılan tetkiklerinde patoloji saptanmayan ağır OUAS.tanısı alan olgularda CPAP tedavisi öncesi subklinik aterosklerozun varlığının değerlendirilmesi amacımızdır. Etik kurul onayı aldıktan sonra prospektif olarak Temmuz 2013-Temmuz 2015 tarihleri arasında ve CPAP tedavi öncesi ve sonrası risk faktörlerine yönelik tetkiklerin(açlık kan şekeri, kolesterol, trigliserit, HDL, LDL, HbA1C, tiroid fonksiyon testleri, homosistein, fibrinojen, Hs CRP ) karşılaştırılması, CPAP tedavisinin bu parametreler üzerine olan etkisinin değerlendirilmesi planlandı. Bulgular: CPAP öncesi elde edilen sonuçlar (homosistein, HsCRP, HbA1C, subklinik hipotiroidi) subklinik aterosklerozu düşündürdü. CPAP öncesi ve sonrası karşılaştırmalı değerlendirmede; trigliserit, HDL,,FT4 değerleri arasında istatiksel açıdan anlamlı fark saptanmaz iken (p:0,346-0,540-0,060) Lökosit, hemoglobin, trombosit, açlık kan şekeri, kolesterol, LDL, homosistein, fibrinojen , FT3, TSH, CRP, Hb A1C değerleri karşılaştırıldığında istatistiksel açıdan anlamlı bulundu.(p:0,003,-0,010,-0,000,-0,001,-0,0080,004-0,000-0,000-0,025-0,000-0,000-0,000) Subklinik hipotiroidi CPAP öncesi 12 hasta mevcutken (%20) CPAP sonrası 5 hastada (%7) subklinik hipotroidi olduğu görüldü. Sonuç: Etkin CPAP (Continous Positive Airway Pressure) tedavisi ile aterosklerozun erken belirteçlerinde dahi iyileşme görülmektedir.

Anahtar Kelime:

Konular: Nörolojik Bilimler

Effects of CPAP (Continous Positive Airway Pressure) Treatment on Oxidative Stress and Pro-Inflammatory Process

Öz:

Introduction: Obstructive sleep apnea syndrome (OSAS) is an independent risk factor for development of atherosclerotic processes because it leads to hypertension, impaired glucose metabolism, obesity and metabolic syndrome, cardiac diseases, elevated blood pressure, and increased level of cholesterol, triglycerides, homocysteine, and coagulation. Materials and Methods: Our aim was to evaluate presence of subclinical atherosclerosis prior to CPAP treatment in the patients with OSAS without any history of previous diseases and any pathological finding in their investigations. After obtaining approval from the Ethics Board, we planned to compare the results of investigations for risk factors for atherosclerosis (fasting blood glucose [FBG], total cholesterol, Triglycerides, HDL- and LDL-cholesterol, thyroid function test, homocysteine, fibrinogen, high sensitivity C-reactive protein [hsCRP]) before and after CPAP treatment and to examine the effect of CPAP treatment on these parameters between July 2013 and July 2015. Findings: Findings obtained before CPAP treatment (homocysteine, hsCRP, HbA1c, subclinical hypothyroidism) suggested subclinical atherosclerosis. In comparative evaluation between the findings before and after CPAP treatment, no statistically significant difference was found in levels of triglycerides, HDL-cholesterol and fT4 (P = 0.346, 0.540, 0.060, respectively) whereas significant differences were found in leukocyte and platelet counts, hemoglobin level, fasting blood glucose, LDL-cholesterol, homocysteine, fibrinogen, fT3, TSH, CRP, and HbA1c (P = 0,003,-0,010,-0,000,-0,001,-0,008-0,004-0,000-0,000-0,0250,000-0,000-0,000, respectively). Subclinical hypothyroidism was present in 12 (20%) patients before CPAP and in 5 (7%) patients after CPAP treatment. Conclusions: Improvement has been seen even in early markers of atherosclerosis with effective CPAP.

Anahtar Kelime:

Konular: Nörolojik Bilimler

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Andreas S, Schulz R, Werner GS, Kreuzer H. Prevalance of obstructive sleep apnea in patients with coronary artery disease. Coron Artery Dis 1996;7:541-5.
2. Basoglu OK, Sarac F, Sarac S, Uluer H, Yilmaz C. Metabolic syndrome, insulin resistance, fibrinogen, homocysteine, leptin, and Creactive protein in obese patients with obstructive sleep apnea syndrome. Ann Thorac Med. 2011 Jul;6(3):120-5. 3.
3. Bielicki P, Przyby?owski T, Kumor M, Barna? M, Wiercioch M, Chazan R. Thyroid Hormone Levels and TSH Activity in Patients with Obstructive Sleep Apnea Syndrome. Adv Exp Med Biol. 2016; 878:67-71.
4. Bixler EO, Vgontzas AN, Lin HM, Ten Have T,Rein J, Vela-Bueno A, Kales A Prevalence of sleep disordered breathing in women: effects of gender. Am J Respir Crit Care Med. 2001; 163 (3 pt 1): 608 - 613.
5. Bokinsky G, Miller M, Ault K, Husband P, Mitchell J. Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure: a preliminary investigation. Chest 1995; 108: 625-30.
6. Celermajer DS, Sürensen K, Ryalls M, Robinson J, Thomas O, Leonard JV, Deanfield JE "Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in the inheterozygous parents", J Am Coll Cardiol 1993; 22: 854- 874.
7. Cereda C, Lavie L, Bassetti CL. Sleep disorders in neurology. New York, NY: Nova Science Publishers, 2012.
8. Chin K, Ohi M, Kita H, Noguchi T, Otsuka N, Tsuboi T, Mishima M, Kuno K. Effects of N CPAP therapy on fibrinogen levels in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 1996; 153: 1972-6.
9. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, Cahill DJ,Emili A, Fitzgerald DJ, Maguire PB. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004;103:2096- 2104.
10. Culebras A. Cerebrovascular disease and sleep. Curr. Neurol Neurosci rep. 2004; 4: 164- 169. 5.
11. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109: III27-32.
12. Drager LF, Jun JC, Polotsky VY. Metabolic consequences of intermittent hypoxia: relevance to obstructive sleep apnea. Best Pract Res Clin Endocrinol Metab 2010;24(5):843-851.
13. Drager LF, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest 2011; 140: 534-42.
14. Durmer JS, Dinges DF. Neurocognitive consequences of sleep deprivation. Semin Neurol. 2005; 25 (1): 117 - 129.
15. El-Solh AA, Mador MJ, Sikka P Dhillon RS, Amsterdam D, Grant BJ.. Adhesion moleculesin patients with coronary artery disease and moderate-to-severe obstructive sleep apnea. Chest 2002; 121: 1541-7.
16. Freynhofer MK, Tajsic M, Wojta J, Huber K. Biomarkers in acute coronary artery disease. Wien Med Wochenschr 2012;162:489-498.
17. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005;115:3378- 3384.
18. Hatipoglu U, Rubinstein I. Inflammation and obstructive sleep apnea syndrome pathogenesis: A working hypothesis. Respiration 2003; 70: 665-71.
19. IP MS, Lam B, Chan LY, Zheng L, Tsang KW, Fung PC, Lam WK . Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Respir Crit Care Med 2000; 162: 2166-71.
20. IP MS, Tse HF, Lam B, Tsang KW, Lam WK. Endothelial function in obstructive sleep apnea and response to treatment. Am j Respir Crit Care Med. 2004; 169: 348-353.
21. Jordan W, Berger C, Cohrs S, Rodenbeck A, Mayer G, Niedmann PD, Von Ahsen N, Rüther E, Kornhuber J, Bleich S. CPAP- therapy effectively lowers serum homocysteine in obstructive sleep apnea syndrome. J Neural Transm 2004; 111: 683-9.
22. Kales A, Caldwell A, Cadieux R, Vela-Bueno A, Ruch L, Mayes S. Severe obstructive sleep apnea -II: Associated psychopathology and psychosocial consequences. J Chron Dis 1985; 38:427 - 434.
23. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N, Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPICNorfolk). BMJ 2001;32215-32218.
24. Köktürk O, Kanbay A. Metabolik sendrom ve obstrüktif uyku apne sendromu. In: Metabolik sendrom yıllığı. Oğuz A. (Ed.). Ankara: Güneş Tıp Kitapevi; 2009.s.133-49.
25. Kumor M, Bielicki P, Przyby?owski T, Rubinsztajn R, Zieli?ski J, Chazan R.Three month continuous positive airway pressure (CPAP) therapy decreases serum total and LDL cholesterol, but not homocysteine and leptin concentration in patients with obstructive sleep apnea syndrome (OUAS)]. Pneumonol Alergol Pol. 2011;79(3):173-83. Polish.
26. Kumor M, Rubinsztajn R, By?kiniewicz K, Bielicki P, Chazan R.[Serum concentration of homocysteine and the risk of atherosclerosis in patients with obstructive sleep apnea syndrome].Pneumonol Alergol Pol. 2006;74(1):117-21. Polish.
27. Kushida CA, Littner MR, Hirshkowitz M, Morgenthaler TI, Alessi CA, Bailey D, Boehlecke B, Brown TM, Coleman J Jr, Friedman L, Kapen S, Kapur VK, Kramer M, Lee-Chiong T, Owens J, Pancer JP, Swick TJ, Wise MS American Academy of Sleep Medicine Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep related breathing disorders. Sleep 2006; 29 (3): 375-380.
28. Lavie L, Hefetz A, Luboshitzky R, Lavie P. Plasma levels of nitric oxide and L-arginine in sleep apnea patients: effects of nCPAP treatment. J Mol Neurosci 2003; 21: 57-64.
29. Lavie L, Perelman A, Lavie P. Plasma homocysteine levels in obstructive sleep apnea association with cardiovascular morbidity. Chest 2001; 120: 900-8.
30. Lavie L. Obstructive sleep apnoea syndrome-an oxidative stres disorder. Sleep Med Rev 2003; 7: 35-51.
31. Lee LA, Chen NH, Huang CG, Lin SW, Fang TJ, Li HY. Patients with severe obstructve sleep apnea syndrome and elevated high sensitivity C-reactive protein need priority treatment. Otolaryngol Head Neck Surgery 2010; 143: 72- 7. 32. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD. "Vascular dysfunction in monkeys with diet induced hyperhomocysteinemia", J Clin Invest 1996; 98: 24-29.141.
33. Libby P. Inflammation in atherosclerosis. Nature 2002;420: 868-74.
34. Lin MT, Lin HH, Lee PL, Weng PH, Lee CC, Lai TC, Liu W, Chen CL. Beneficial effect of continuous positive airway pressure on lipid profiles in obstructive sleep apnea: a metaanalysis. Sleep Breath. 2015 sep;19(3):809-17.
35. Malhotra A, White DP. Obstructive sleep apnoea. Lancet 2002; 360: 237-45.
36. Milleron O, Pilliere R, Foucher A, de Roquefeuil F, Aegerter P, Jondeau G, Raffestin BG, Dubourg O. Benefits of obstructive sleep apnoea treatment in coronary artery disease: a long term follow-up study. Eur Heart J 2004; 25: 728-734.
37. Mohsenin V, Valor R. Sleep apnea in patients with hemispheric stroke. Arch Phys Med Rehabil 1995;76:71-6.
38. Mooe T, Rabben T, Wiklund U, Franklin KA, Eriksson P. Sleep-disordered breathing in men with coronary artery disease. Chest 1996;109:659-63.
39. Nadeem R, Singh M, Nida M, Waheed I, Khan A, Ahmed S, Naseem J, Champeau D. Effect of obstructive sleep apnea hypopnea syndrome on lipid profile: a meta -regression analysis. J Clin Sleep Med 2014;10(5):475-489.
40. Ozcan KM, Selcuk A, Ozcan I, Ozdas T, Ozdogan F, Acar M, Dere H Incidence of hypothyroidism and its correlation with polysomnography findings in obstructive sleep apnea. Eur Arch Otorhinolaryngol. 2014 Nov;271(11):2937-41.
41. Partinen M, Jamieson A, Guilleminault C. Long-term outcome for obstructive sleep apnea syndrome patients: mortality. Chest 1988; 94(12): 1200-4.
42. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J. Increased incidence of 43. Peltier A.C, Consens F.B, Sheikh K, Wang L, Song Y, Russell J. W, "Autonomic dysfunction in obstructive sleep apnea is associated with impaired glucose regulation," Sleep Medicine 2007; 8 (2): 149-155.
44. Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proc Am Thorac Soc 2008; 5: 136-143.
45. Reichmuth K. J, Austin D, Skatrud J. B, Young T. "Association of sleep apnea and type II diabetes: a population-based study," American Journal of Respiratory and Critical CareMedicine 2005; 172 (12): 1590-1595.
46. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138(5 Pt 2): 419-20.
47. Schafer H, Koahler U, Ploch T, Peter JH. Sleep-related myocardial ischemia and sleep structure in patients with obstructive sleep apnea and coronary heart disease. Chest 1997; 11 (2): 387-93.
48. Schulz R, Schmidt D, Blum A, Lopes-Ribeiro X, Lücke C, Mayer K, Olschewski H, seeger W, Grimminger F. Decreased plasma levels of nitric oxide derivative in obstructive sleep apnoea: response to nCPAP therapy. Thorax 2000; 55: 1046-51.
49. Sedeek MH, Llinas MT, Drummond H, Fortepiani L, Abram SR, Alexander BT, Reckelhoff JF, Granger JP. Role of reactive oxygen species in endothelin-induced hypertension. Hypertension. 2003; 42: 806- 810.
50. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA 2003; 290: 1906-14.
51. Shamsuzzaman AS, Somers VK. Fibrinogen, stroke and obstructive sleep apnea: an evolving paradigm of cardiovascular risk. Am J Respir Crit Care Med 2000; 162: 2018-20.
52. Shamsuzzaman AS, Winnicki M, Lanfranchi P, Wolk R, Kara T, Accurso V, Somers VK. Elevated C reactive protein in patients with obstructive sleep apnea. Circulation 2002; 105: 2462-4.
53. Sharma SK, Agrawal S, Damodaran D, Sreenivas V, Kadhiravan T, Lakshmy R, Jagia P, Kumar A. CPAP for the metabolic syndrome in patients with obstructive sleep apnea. N Engl J Med 2011; 365: 2277-86.
54. Spiegel, K. Leproult, R. and Van Cauter, E. "Impact of sleep debt on metabolic and endocrine function," The Lancet 1999; 354 (9188): 1435-1439.
55. Stamatakis KA, Punjabi NM. Effects of sleep fragmentation on glucose metabolism in normal subjects. Chest 2010; 137: 95-101.
56. Surani S, Subramanian S. Effect of continuous positive airway pressure therapy on glucose control. World J Diabetes 2012; 3: 65-70.
57. Suzuki YJ, Jain V, Park AM, Day RM. Oxidative stress and oxidant signaling in obstructive sleep apnea and associated
58. Svatikova A, Wolk R, Magera MJ, Shamsuzzaman AS, Phillips BG, Somers VK. Plasma homocysteine in obstructive sleep apnea. European Heart Journal 2004; 25: 1325-9.
59. Tasali E, Mokhlesi B, Van Cauter E. "Obstructive sleep apnea and type 2 diabetes: interacting epidemics," Chest 2008; 133 (2): 496-506.
60. Van den Berg M, Boers GH, Franken DG, Blom HJ, Van Kamp GJ, Jakobs C, Rauwerda JA, Kluft C, Stehouwert CD. "Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease". Eur J Clin Invest; 25: 176-81, 1995.140.
61. Verstraeten E. Neurocognitive effects of obstructive sleep apnea syndrome. Curr Neurol Neurosci Rep. 2007;7 (2): 161 - 166.
62. Vgontzas A.N, Papanicolaou D.A, Bixler E.O, Kales A, Tyson K, Chrousos G.P, "Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity," Journal of Clinical Endocrinology and Metabolism, 1997; 82(5):1313-6.
63. Wessendorf TE, Thilman AF, Wang YM, Schreiber A, Konietzko N, Teschler H. Fibrinogen levels and obstructive sleep apnea in ischemic stroke. Am J Respir Crit Care Med 2000; 162: 2039-42.
64. Wilcox I, Mcnamara SG, Collins FL, Grunstein RR, Sullivan CE. "Syndrome Z": The interaction of sleep apnea, vascular risk factors and heart disease. Thorax 1998; 53(Suppl 3): 25-8.
65. Wiwanitkit S, Wiwanitkit V. Insulin resistance, fibrinojen, homocysteine, leptin, and C-reactive protein and metabolic syndrome. Annals of Thoracic Medicine 2011;6(4):243.
66. Wu WT, Tsai SS Shih TS, Lin MH, Chou TC, Ting H, Wu TN, Liou SH The impact of obstructive sleep apnea on high-sensitivity Creactive protein in subjects with or without metabolic syndrome. Sleep Breath. 2015 Dec;19(4):1449-57.
67. Yokoe T, Minoguchi K, Matsuo H, Oda N, Minoguchi H, Yoshino G, HiranoT, Adachi M. Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003; 107: 1129-34.
68. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurence of sleep disordered breathing among middle-aged adults. N Eng J Med 1993; 328: 1230-1235.

APA	KISABAY A, SARI U, ALDEMİR E, OKTAN B, KORKMAZ T, Dinç Horasan G, YILMAZ H (2016). CPAP ( Continous Positive Airway Pressure) Tedavisinin Oksidatif Stres ve Pro- İnflamatuar Sürece Olan Etkisi. , 264 - 277.
Chicago	KISABAY Ayşin,SARI U Serpil,ALDEMİR Eda ÇAKIROĞLU,OKTAN Bilge,KORKMAZ Tuğba KORKMAZ,Dinç Horasan Gönül,YILMAZ Hikmet CPAP ( Continous Positive Airway Pressure) Tedavisinin Oksidatif Stres ve Pro- İnflamatuar Sürece Olan Etkisi. (2016): 264 - 277.
MLA	KISABAY Ayşin,SARI U Serpil,ALDEMİR Eda ÇAKIROĞLU,OKTAN Bilge,KORKMAZ Tuğba KORKMAZ,Dinç Horasan Gönül,YILMAZ Hikmet CPAP ( Continous Positive Airway Pressure) Tedavisinin Oksidatif Stres ve Pro- İnflamatuar Sürece Olan Etkisi. , 2016, ss.264 - 277.
AMA	KISABAY A,SARI U,ALDEMİR E,OKTAN B,KORKMAZ T,Dinç Horasan G,YILMAZ H CPAP ( Continous Positive Airway Pressure) Tedavisinin Oksidatif Stres ve Pro- İnflamatuar Sürece Olan Etkisi. . 2016; 264 - 277.
Vancouver	KISABAY A,SARI U,ALDEMİR E,OKTAN B,KORKMAZ T,Dinç Horasan G,YILMAZ H CPAP ( Continous Positive Airway Pressure) Tedavisinin Oksidatif Stres ve Pro- İnflamatuar Sürece Olan Etkisi. . 2016; 264 - 277.
IEEE	KISABAY A,SARI U,ALDEMİR E,OKTAN B,KORKMAZ T,Dinç Horasan G,YILMAZ H "CPAP ( Continous Positive Airway Pressure) Tedavisinin Oksidatif Stres ve Pro- İnflamatuar Sürece Olan Etkisi." , ss.264 - 277, 2016.
ISNAD	KISABAY, Ayşin vd. "CPAP ( Continous Positive Airway Pressure) Tedavisinin Oksidatif Stres ve Pro- İnflamatuar Sürece Olan Etkisi". (2016), 264-277.

APA	KISABAY A, SARI U, ALDEMİR E, OKTAN B, KORKMAZ T, Dinç Horasan G, YILMAZ H (2016). CPAP ( Continous Positive Airway Pressure) Tedavisinin Oksidatif Stres ve Pro- İnflamatuar Sürece Olan Etkisi. Journal of Neurological Sciences (Turkish), 33(2), 264 - 277.
Chicago	KISABAY Ayşin,SARI U Serpil,ALDEMİR Eda ÇAKIROĞLU,OKTAN Bilge,KORKMAZ Tuğba KORKMAZ,Dinç Horasan Gönül,YILMAZ Hikmet CPAP ( Continous Positive Airway Pressure) Tedavisinin Oksidatif Stres ve Pro- İnflamatuar Sürece Olan Etkisi. Journal of Neurological Sciences (Turkish) 33, no.2 (2016): 264 - 277.
MLA	KISABAY Ayşin,SARI U Serpil,ALDEMİR Eda ÇAKIROĞLU,OKTAN Bilge,KORKMAZ Tuğba KORKMAZ,Dinç Horasan Gönül,YILMAZ Hikmet CPAP ( Continous Positive Airway Pressure) Tedavisinin Oksidatif Stres ve Pro- İnflamatuar Sürece Olan Etkisi. Journal of Neurological Sciences (Turkish), vol.33, no.2, 2016, ss.264 - 277.
AMA	KISABAY A,SARI U,ALDEMİR E,OKTAN B,KORKMAZ T,Dinç Horasan G,YILMAZ H CPAP ( Continous Positive Airway Pressure) Tedavisinin Oksidatif Stres ve Pro- İnflamatuar Sürece Olan Etkisi. Journal of Neurological Sciences (Turkish). 2016; 33(2): 264 - 277.
Vancouver	KISABAY A,SARI U,ALDEMİR E,OKTAN B,KORKMAZ T,Dinç Horasan G,YILMAZ H CPAP ( Continous Positive Airway Pressure) Tedavisinin Oksidatif Stres ve Pro- İnflamatuar Sürece Olan Etkisi. Journal of Neurological Sciences (Turkish). 2016; 33(2): 264 - 277.
IEEE	KISABAY A,SARI U,ALDEMİR E,OKTAN B,KORKMAZ T,Dinç Horasan G,YILMAZ H "CPAP ( Continous Positive Airway Pressure) Tedavisinin Oksidatif Stres ve Pro- İnflamatuar Sürece Olan Etkisi." Journal of Neurological Sciences (Turkish), 33, ss.264 - 277, 2016.
ISNAD	KISABAY, Ayşin vd. "CPAP ( Continous Positive Airway Pressure) Tedavisinin Oksidatif Stres ve Pro- İnflamatuar Sürece Olan Etkisi". Journal of Neurological Sciences (Turkish) 33/2 (2016), 264-277.